Loading clinical trials...
Loading clinical trials...
A Phase II, Open-Label, Single-Arm, Multicenter Study to Evaluate the Safety and Immunogenicity of a Trivalent, Surface Antigen Inactivated Subunit Influenza Virus Vaccine Including MF59C.1 Adjuvant (Fluad®) in Healthy Adults ≥65 Years of Age
Conditions
Interventions
aTIV
Locations
1
Belgium
Antwerp University Centre for the Evaluation of Vaccination
Antwerp, Wilrijk, Belgium
Start Date
July 1, 2013
Primary Completion Date
August 1, 2013
Completion Date
August 1, 2013
Last Updated
March 26, 2014
NCT04682444
NCT04431050
NCT02387294
NCT03448705
NCT03572491
NCT01651104
Lead Sponsor
Novartis Vaccines
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions